Vivimed Labs Ltd Share Price Vivimed Labs.

22.10

Open ()
Turnover (lac)
Prev. Close ()
Day's Vol.(shares)

22.10

Open ()
Turnover (lac)
Prev. Close ()
Day's Vol.(shares)
Detailed Quote

Corporate Action

Period From
Period To
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 16-Apr-2019 - -
Allotment of Shares pursuant to exercise of Employee Stock Options under the Vivimed Labs ESOS 2010 We wish to inform you that the Nomination And Remuneration Committee of the Board of Directors of the Company through a resolution passed at its meeting held on 16th April, 2019, has allotted 3,90,000 equity shares of Rs.2/- each fully paid up to the allottees upon exercise of stock options pursuant to Vivimed Labs ESOS 2010 With the allotment of the above shares, the equity base of the Company stands increased from present level of 8,25,23,915 (Nos.) to 8,29,13,915 (Nos.) equity shares of Rs.2/- each. CANCELLATION OF STOCK OPTIONS: The Nomination and Remuneration Committee at its Meeting held on 16th April, 2019 took note of cancellation of 6,05,000 Stock Options granted under Vivimed Labs ESOS 2010.
Board Meeting - 04-Feb-2019 - -
VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2019 ,inter alia, to consider and approve With reference to the captioned subject, this is to inform you that a meeting of the Board of Directors of the Company will be held on Thursday, February 14, 2019, inter alia, to consider and approve the unaudited Financial Results of the Company for the quarter ended 31/12/2018. In view of this, pursuant to SEBI (Prohibition of Insider Trading) Regulations and Companys Internal Code for Prevention of Insider Trading, the trading window for dealing in securities of the Company shall remain closed from February 04, 2019 to February 14, 2019 (both days inclusive) and shall reopen after the expiry of 48 hours after the public announcement of unaudited financial results is made. The Board of Directors of the Company at its meeting held on Thursday, February 14, 2019 inter alia, have approved / resolved/ taken note of the following: 1. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, considered and approved the submission of the Un audited Financial Results (Standalone & Consolidated) for the Quarter and 9 months ended December 31, 2018 attached herewith; 2. Auditorss Limited Review Report on the Un-audited Financial Statements of the Company for the Quarter and 9 months ended December 31, 2018. An earnings related presentation including business highlights will be uploaded on the companys website www.vivimedlabs.com (As Per BSE Announcement Dated 14.02.2019)
Board Meeting - 01-Nov-2018 - -
VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2018 ,inter alia, to consider and approve Notice of Board Meeting for considering unaudited financial results for the quarter and half year ended 30/09/2018 & Closure of Trading Window Outcome of the Meeting of the Board of Directors of the Company (As Per BSE Announcement Dated on 14.11.2018)
Board Meeting - 23-Aug-2018 - -
Outcome of the Meeting of the Board of Directors of the Company
Board Meeting - 01-Aug-2018 - -
Quarterly Results VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2018 ,inter alias, to consider and approve With reference to the captioned subject, this is to inform you that a meeting of the Board of Directors of the Company will be held on Monday, August 13, 2018, inter alia, to consider and approve the unaudited Financial Results of the Company for the quarter ended 30/06/2018 and other items if any. In view of this, pursuant to SEBI (Prohibition of Insider Trading) Regulations and Companys Internal Code for Prevention of Insider Trading, the trading window for dealing in securities of the Company shall remain closed from August 01, 2018 to August 13, 2018 (both days inclusive) and shall reopen after the expiry of 48 hours after the public announcement of unaudited financial results is made. Q1 Result FY 2019 (As Per BSE Announcement Dated on 13.08.2018)
Board Meeting - 18-May-2018 - -
Vivimed Labs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 30, 2018, inter alia, to consider and approve the audited Financial Results of the Company for the quarter and year ended March 31, 2018 and to consider, recommend dividend for the FY 2017 -2018, if any.In view of this, pursuant to SEBI (Prohibition of Insider Trading) Regulations and Companys Internal Code for Prevention of Insider Trading, the trading window for dealing in securities of the Company shall remain closed from May 18, 2018 to May 30, 2018 (both days inclusive) and shall reopen after the expiry of 48 hours after the public announcement of audited financial results is made. With reference to the captioned subject, this is to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday, May 30, 2018, inter alia, to consider and approve the audited Financial Results of the Company for the quarter and year ended 31/03/2018 and to consider, recommend dividend for the FY 2017-2018, if any. In view of this, pursuant to SEBI (Prohibition of Insider Trading) Regulations and Companys Internal Code for Prevention of Insider Trading, the trading window for dealing in securities of the Company shall remain closed from May 18, 2018 to May 30, 2018 (both days inclusive) and shall reopen after the expiry of 48 hours after the public announcement of audited financial results is made. Vivimed Labs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 30, 2018, inter alia, to consider and approve the audited Financial Results of the Company for the quarter and year ended March 31, 2018 and to consider, recommend dividend for the FY 2017 -2018, if any. In view of this, pursuant to SEBI (Prohibition of Insider Trading) Regulations and Companys Internal Code for Prevention of Insider Trading, the trading window for dealing in securities of the Company shall remain closed from May 18, 2018 to May 30, 2018 (both days inclusive) and shall reopen after the expiry of 48 hours after the public announcement of audited financial results is made. Vivimed Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2018, inter alia, has recommended, subject to the approval of shareholders, payment of Dividend of Rs. 0.40/- (Forty paise) per equity share of Rs. 2/- each (20%), to the equity shareholders of the Company for the Financial Year 2017-2018. The saiddividend, if approved by shareholders, will be credited /despatched to those members entitled thereto as per record date/Book closure date to be decided subsequently. (As Per BSE Announcement Dated on 5/30/2018 9:28:21 PM)